Paolo Tarantino: How do the results of DESTINY-Breast06 change our practice?
Paolo Tarantino shared on LinkedIn:
“How do the results of DESTINY-Breast06 change our practice?
Should T-DXd be used to treat HER2-ultralow metastatic breast cancer?
How should T-DXd now be sequenced with other therapies, such as oral chemotherapy or other antibody-drug conjugates?
At Dana-Farber Cancer Institute we routinely conduct internal polls on practice-changing data to produce Consensus Guidelines. All of these consensus are publicly available on our website.
Read the T-DXd Consensus document here.”
Source: Paolo Tarantino/LinkedIn
More posts featuring Paolo Tarantino on oncodaily.com
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023